$30SAVE with the Affordable Medication Solutions RX Savings CardUP TO
COPAY
ON
Privately-Insured Patients
* This coupon is not valid for prescriptions reimbursed under Medicare, Medicaid, or any other federal or state program, or where prohibited by law. Where third party reimbursement covers a portion of your prescriptions, this coupon is valid only for a portion of the amount of your actual out-of-pocket expenses. Offer valid only for prescriptions filled in the United States. Affordable Medication Solutions reserves the right to discontinue this offer at any time. This coupon cannot be combined with any other rebate or coupon, free trial, or similar offer for the specified prescription. The discount will be accepted only at participating pharmacies.
If you do not wish to further participate in this cost-saving program, call 1-844-285-1848 to opt out of the program.
This is not a form of insurance.* Present this card to receive savings up to $30 (maximum benefit). Some restrictions
apply.
BIN: 610322
MEMBER ID:PATIENT’S LAST NAME ANDFIRST INITIAL
PERSON CODE: 01
GROUP: GEN-AS-1 INS
Astero 30mL $30.00
Gensco Pharma Launches the First FDA Approved Prescription Hydrogel with 4% Lidocaine HCL for Wound Pain
August 22, 2016
Gensco Pharma announces Astero™, a FDA approved prescription hydrogel which contains the topical anesthetic lidocaine hydrochloride. Astero™ is indicated for painful wounds such as post-surgical incisions, ulcers, cuts and abrasions.
Astero™ is specifically formulated to create a moist healing environment, which promotes granulation, epithelialization, and autolytic debridement, while providing prolonged anesthesia of the wound, lessening the need for systemic pain medications including opiate based drugs. “Astero™ provides the clinician a proven and trusted first line wound dressing for post-surgical incisions, cuts, ulcers and abrasions. The soothing hydrogel creates a superior wound healing environment while the lidocaine component imparts sustained pain control of the wound,” says Dr. Brenner.
“Since our inception, our corporate focus is to utilize our resources on innovative research and the development of unique delivery systems to improve access to products providing improved quality of life for patients who suffer from pain and debilitating diseases,” said Carlos Alfaras, CEO of Gensco Pharma. “Our blend of science and understanding of the value proposition to patients and industry partners drives us to develop improved outcomes for all. Astero is a perfect example of Gensco Pharma at work, including the clinical perspective and the ability to assist with the financial burden to patients with our copay assistance programs.”
Astero™ is offered through national wholesalers, chain pharmacies and Group Purchasing Organizations including but not limited to: McKesson, Cardinal, AmerisourceBergen, HD Smith, Walgreens, CVS, Intalere, Innovatix and MedAssets.
For more information on Astero™, visit www.asterogel.com.
Wound management is one of the most common aspects of podiatric practice.
The etiology of the wound may vary from post-surgical, traumatic, or disease state progression but the treatment goal is the
early, provides the best chance for resolution especially in patients
-
Once a wound has been assessed, debrided, cultured, and
photographed, a hydrogel type dressing is an excellent
the ability to donate water molecules to dehydrated tissue
while allowing the passage of water vapor and oxygen to the
phagocytic activity of leucocytes and enzymatic activity of
during the early phase of wound healing and limits the
1 More so, the hydrogel does not
adhere to the wound surface thereby preventing tissue
Frequently, pain as a result of trauma, particularly during the
dressing change procedure, has been described by patients 2
management strategy is a key component in the treatment
for background pain and the pain arising from wound proce-
injuries recommend prescribers should explore non opioid
medications and other modalities that can be used to
3 Many clinicians
use a topical anesthetic agent, lidocaine, to manage wound
pain during procedures such as debridement and dressing
Though pain control is often the patients primary concern,
clinicians are more likely concerned with wound healing and
-
5
™ is the new prescription hydrogel wound product in
™, which contains the topical anesthetic
environment, which promotes granulation, epithelialization,
and autolytic debridement, while providing prolonged
anesthesia of the wound, lessening the need for systemic
the hydrogel in combination with Meadowsweet and Oak
Extract helps suppress the development of wound
infections, increasing wound healing rates and decreasing
Oak extract has been studied for its ability to suppress
-6
continuation of this study, evaluating burn wounds, oak
extract was demonstrated to not only suppress bacterial
infection but increase the rate of healing, leading the
authors to suggest that the oak bark formulation can
enhance the migration of epidermal cells to accelerate
6
was shown to be superior to silver sulfadiazine cream in
™, available by prescription only, provides the clinician -
hydrogel containing Meadowsweet and Oak Extract create a
superior wound healing environment while the lidocaine
Though this data supports the need for continued clinical
trials to better understand wound healing, podiatric practi-
tioners now have a valuable new topical wound hydrogel to
______________
-
Advances in Treatment of Painful Wounds
by Marc Alan Brenner, DPM, The Institute for Diabetic Foot Research
Dr. Marc A. Brenner is a past President and Fellow of the American Society of Podiatric Dermatology. He is a renown national and international lecturer in the areas of podiatric dermatology and
About Gensco Pharma: Gensco Pharma is a specialty pharmaceutical company focusing on research, development and marketing of transdermal prescription products. As an innovator of pharmaceutical products and the development of patented drug delivery systems, Gensco is dedicated to the continual pursuit of novel and effective therapies that improve health.
New Product Update
GENSCO PHARMAA Specialty Pharmaceutical Company
genscopharma.com
[email protected] 543-6726855 5GENSCO
FAX855 743-6726855 7GENSCO
OFFICE
